For instance, PACs may reduce hyperglycemia through the regulation of GLUT2 transporters: in addition to stimulate basal glucose uptake into human HepG2 cells by significantly increasing GLUT2 expression (1.9–3.12-fold) [220], PACs can revert the decreased extracellular glucose consumption triggered by insulin pre-treatment, leading to an insulin sensitivity improvement similar to that observed upon treatment with metformin [242]. This evidence concerns the gene INS and Hyperglycemia.